{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:55:45Z","timestamp":1789181745287,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04722-z","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:39:19Z","timestamp":1733726359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients"],"prefix":"10.1007","volume":"95","author":[{"given":"Chalirmporn","family":"Atasilp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natchaya","family":"Vanwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavitchaya","family":"Yodwongjane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phichai","family":"Chansriwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaphop","family":"Sirachainan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyanan","family":"Reungwetwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimonpan","family":"Jinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somthawin","family":"Aiempradit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwannee","family":"Sirilerttrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monpat","family":"Chamnanphon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipaporn","family":"Sankuntaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patompong","family":"Satapornpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fabienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"2","key":"4722_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2125.2010.03686.x","volume":"70","author":"H Mounier-Boutoille","year":"2010","unstructured":"Mounier-Boutoille H, Boisdron-Celle M, Cauchin E et al (2010) Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation. Br J Clin Pharmacol Aug 70(2):280\u2013283. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03686.x","journal-title":"Br J Clin Pharmacol Aug"},{"issue":"3","key":"4722_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/iub.1361","volume":"67","author":"J Chai","year":"2015","unstructured":"Chai J, Dong W, Xie C et al (2015) MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life Mar 67(3):191\u2013201. https:\/\/doi.org\/10.1002\/iub.1361","journal-title":"IUBMB Life Mar"},{"issue":"12","key":"4722_CR3","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/bjc.2013.262","volume":"25","author":"A Loganayagam","year":"2013","unstructured":"Loganayagam A, Arenas Hernandez M, Corrigan A et al (2013) Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer Jun 25(12):2505\u20132515. https:\/\/doi.org\/10.1038\/bjc.2013.262","journal-title":"Br J Cancer Jun"},{"issue":"4","key":"4722_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2217\/fon.09.26","volume":"5","author":"YI Kim","year":"2009","unstructured":"Kim YI (2009) Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol May 5(4):523\u2013542. https:\/\/doi.org\/10.2217\/fon.09.26","journal-title":"Future Oncol May"},{"issue":"3","key":"4722_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.21037\/jgo.2018.02.03","volume":"9","author":"M Khushman","year":"2018","unstructured":"Khushman M, Patel GK, Hosein PJ et al (2018) Germline pharmacogenomics of DPYD*9A (c.85T\u2009>\u2009C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. J Gastrointest Oncol Jun 9(3):416\u2013424. https:\/\/doi.org\/10.21037\/jgo.2018.02.03","journal-title":"J Gastrointest Oncol Jun"},{"key":"4722_CR6","unstructured":"Dean L, Kane M et al (2012) Fluorouracil Therapy and DPYD Genotype. In: Pratt VM, Scott SA, Pirmohamed M, eds. Medical Genetics Summaries"},{"issue":"12","key":"4722_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving Fluoropyrimidine Chemotherapy: a systematic review and Meta-analysis. Oncologist Dec 26(12):1008\u20131016. https:\/\/doi.org\/10.1002\/onco.13967","journal-title":"Oncologist Dec"},{"issue":"6","key":"4722_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/clpt.2013.172","volume":"94","author":"KE Caudle","year":"2013","unstructured":"Caudle KE, Thorn CF, Klein TE et al (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther Dec 94(6):640\u2013645. https:\/\/doi.org\/10.1038\/clpt.2013.172","journal-title":"Clin Pharmacol Ther Dec"},{"key":"4722_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2153-0645.1000112","volume":"3","author":"E Sirachainan","year":"2012","unstructured":"Sirachainan E, Reungwetwattana T, Wisetpanit Y et al (2012) Pharmacogenetic study of 5-Fluorouracil-related severe toxicity in Thai Cancer patients: a novel SNP detection. J Pharmacogenomics Pharmacoproteomics 3:1\u20134","journal-title":"J Pharmacogenomics Pharmacoproteomics"},{"key":"4722_CR10","doi-asserted-by":"publisher","unstructured":"Lee AM, Shi Q, Pavey E et al (2014) DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst Dec 106(12). https:\/\/doi.org\/10.1093\/jnci\/dju298","DOI":"10.1093\/jnci\/dju298"},{"issue":"2","key":"4722_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/FTD.0b013e318040b1fe","volume":"29","author":"HJ Cho","year":"2007","unstructured":"Cho HJ, Park YS, Kang WK, Kim JW, Lee SY (2007) Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Therapeutic drug Monit Apr 29(2):190\u2013196. https:\/\/doi.org\/10.1097\/FTD.0b013e318040b1fe","journal-title":"Therapeutic drug Monit Apr"},{"issue":"3","key":"4722_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s004390050637","volume":"101","author":"P Vreken","year":"1997","unstructured":"Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH (1997) Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet Dec 101(3):333\u2013338. https:\/\/doi.org\/10.1007\/s004390050637","journal-title":"Hum Genet Dec"},{"issue":"3","key":"4722_CR13","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/j.clcc.2019.04.005","volume":"18","author":"AS Maharjan","year":"2019","unstructured":"Maharjan AS, McMillin GA, Patel GK et al (2019) The prevalence of DPYD*9A(c.85T\u2009>\u2009C) Genotype and the genotype-phenotype correlation in patients with gastrointestinal malignancies treated with fluoropyrimidines: updated analysis. Clin Colorectal Cancer Sep 18(3):e280\u2013e286. https:\/\/doi.org\/10.1016\/j.clcc.2019.04.005","journal-title":"Clin Colorectal Cancer Sep"},{"key":"4722_CR14","doi-asserted-by":"publisher","unstructured":"Varma A, Jayanthi M, Dubashi B, Shewade DG, Sundaram R (2020) Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of south Indian origin. Drug Metab Pers Ther Sep 23(4). https:\/\/doi.org\/10.1515\/dmpt-2020-0133","DOI":"10.1515\/dmpt-2020-0133"},{"issue":"2","key":"4722_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/bf02698048","volume":"24","author":"H Zhang","year":"2007","unstructured":"Zhang H, Li YM, Zhang H, Jin X (2007) DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 24(2):251\u2013258. https:\/\/doi.org\/10.1007\/bf02698048","journal-title":"Med Oncol"},{"issue":"4","key":"4722_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00280-015-2698-7","volume":"75","author":"M Joerger","year":"2015","unstructured":"Joerger M, Huitema AD, Boot H et al (2015) Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol Apr 75(4):763\u2013772. https:\/\/doi.org\/10.1007\/s00280-015-2698-7","journal-title":"Cancer Chemother Pharmacol Apr"},{"issue":"6","key":"4722_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/humu.9201","volume":"22","author":"E Gross","year":"2003","unstructured":"Gross E, Ullrich T, Seck K et al (2003) Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat Dec 22(6):498. https:\/\/doi.org\/10.1002\/humu.9201","journal-title":"Hum Mutat Dec"},{"key":"4722_CR18","unstructured":"Bain BJ (2011) CHAPTER 5 - Pathology of the marrow: General considerations and infections\/reactive conditions. In: Porwit A, McCullough J, Erber WN, eds. Blood and Bone Marrow Pathology (Second Edition). Churchill Livingstone;:79\u2013102"},{"issue":"5","key":"4722_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/FTD.0b013e318290acd2","volume":"35","author":"LK Teh","year":"2013","unstructured":"Teh LK, Hamzah S, Hashim H et al (2013) Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. Therapeutic drug Monit Oct 35(5):624\u2013630. https:\/\/doi.org\/10.1097\/FTD.0b013e318290acd2","journal-title":"Therapeutic drug Monit Oct"},{"issue":"3","key":"4722_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2710.2008.00898.x","volume":"33","author":"YF He","year":"2008","unstructured":"He YF, Wei W, Zhang X et al (2008) Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J Clin Pharm Ther Jun 33(3):307\u2013314. https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00898.x","journal-title":"J Clin Pharm Ther Jun"},{"issue":"6","key":"4722_CR21","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.Can-12-3858","volume":"15","author":"SM Offer","year":"2013","unstructured":"Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB (2013) Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res Mar 15(6):1958\u20131968. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-3858","journal-title":"Cancer Res Mar"},{"issue":"4","key":"4722_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbadis.2016.01.009","volume":"1862","author":"A Kuilenburg","year":"2016","unstructured":"Kuilenburg A, Meijer J, Tanck MWT et al (2016) Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochim Biophys Acta Apr 1862(4):754\u2013762. https:\/\/doi.org\/10.1016\/j.bbadis.2016.01.009","journal-title":"Biochim Biophys Acta Apr"},{"key":"4722_CR23","doi-asserted-by":"publisher","unstructured":"Yamashita K, Mikami Y, Ikeda M, et al. Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. Cancer Letters. 2002\/12\/15\/ 2002;188(1):231\u2013236. https:\/\/doi.org\/10.1016\/S0304-3835(02)00435-4","DOI":"10.1016\/S0304-3835(02)00435-4"},{"key":"4722_CR24","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.crphar.2022.100152","volume":"4","author":"HT Rakshith","year":"2023","unstructured":"Rakshith HT, Lohita S, Rebello AP, Goudanavar PS, Raghavendra Naveen N (2023) Sex differences in drug effects and\/or toxicity in oncology. Curr Res Pharmacol Drug Discov 4:100152. https:\/\/doi.org\/10.1016\/j.crphar.2022.100152","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"17","key":"4722_CR25","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1158\/1078-0432.CCR-04-0169","volume":"1","author":"T Lecomte","year":"2004","unstructured":"Lecomte T, Ferraz JM, Zinzindohoue F et al (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res Sep 1(17):5880\u20135888. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0169","journal-title":"Clin Cancer Res Sep"},{"issue":"1","key":"4722_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00280-017-3478-3","volume":"81","author":"NA Nahid","year":"2018","unstructured":"Nahid NA, Apu MNH, Islam MR et al (2018) DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer Chemother Pharmacol Jan 81(1):119\u2013129. https:\/\/doi.org\/10.1007\/s00280-017-3478-3","journal-title":"Cancer Chemother Pharmacol Jan"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04722-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04722-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04722-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T07:03:01Z","timestamp":1733727781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04722-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4722"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04722-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"27 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}